Analysis The Treatment Of Imatinib In Chronic Myeloid Leukemia Of Chronic Phase About The Different Ethnic Group

Objective:To evaluate the efficacy and prognosis of imatinib in treatmem 0f chronic myeloid leukemia(CML)patients between the Han and Uighur ethnic group.Methods:the chronic phase CML patients who received imatinib from September2006 to December 2016 were collected in the Blood Center of the First Affiliated Hospital in Xinjiang Medical University.The follow-up date was as of March 2017.The influencing factors on the outcome of treatment and the difference between Han and Uygur patients were analyzed.Results:One hundred and sixty-one patients were evaluable,including 116 Han patients and 45 Uighurs,with a male to female ratio of 1.7:1 ? Analysis in age,gender and white blood cell count,platelet count and anemia,splenomegaly distribution,Sokal score between the Han and Uighur ethnic group,this dates show no statistical significance.According to the Sokal score,The research shows that there are significant differences among the three groups at low risk,moderate risk and high risk.Analysis the imatinib treatment of two groups,there was no significant difference in the optimal response rate at 3 months and 6 months after treatment.The best reaction rates of Han and Uyghur in 12 months were 77.5% and 46.6% respectively(P =0.048).The expected OS rates at 120 months after treatment in Han and Uigur ethnic groups were(84.9 ± 10.1)% and(85.8 ± 6.9)%,respectively.The expected PFS rates at120 months after treatment in Han and Uygur nationality patients were(74.33 ± 5.9)%and(64.4 ± 10.0)%,respectively(P=0.029).Uygur patients develop disease earlier than Han patients with chronic CML.Conclusion:There were significant differences among the three groups at low risk,mediate risk and high risk.The rates of the best molecular response in low-risk patients are significantly higher than those in internlediate-risk and high-risk patient.The treatment effect and survival time of CML patients in CP withimatinib is not difference between Han and Uygur patients.Uygur patients are more prone to disease progression than the Han nationality and needs to be verified in more cases.